These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16895581)

  • 21. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.
    Klivenyi P; Ferrante RJ; Matthews RT; Bogdanov MB; Klein AM; Andreassen OA; Mueller G; Wermer M; Kaddurah-Daouk R; Beal MF
    Nat Med; 1999 Mar; 5(3):347-50. PubMed ID: 10086395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis.
    Andreassen OA; Ferrante RJ; Klivenyi P; Klein AM; Shinobu LA; Epstein CJ; Beal MF
    Ann Neurol; 2000 Apr; 47(4):447-55. PubMed ID: 10762155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis.
    Kabashi E; Agar JN; Taylor DM; Minotti S; Durham HD
    J Neurochem; 2004 Jun; 89(6):1325-35. PubMed ID: 15189335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid.
    Raman C; McAllister SD; Rizvi G; Patel SG; Moore DH; Abood ME
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Mar; 5(1):33-9. PubMed ID: 15204022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukemia inhibitory factor by systemic administration rescues spinal motor neurons in the SOD1 G93A murine model of familial amyotrophic lateral sclerosis.
    Azari MF; Galle A; Lopes EC; Kurek J; Cheema SS
    Brain Res; 2001 Dec; 922(1):144-7. PubMed ID: 11730713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment.
    Weishaupt JH; Bartels C; Pölking E; Dietrich J; Rohde G; Poeggeler B; Mertens N; Sperling S; Bohn M; Hüther G; Schneider A; Bach A; Sirén AL; Hardeland R; Bähr M; Nave KA; Ehrenreich H
    J Pineal Res; 2006 Nov; 41(4):313-23. PubMed ID: 17014688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis.
    Ferrante RJ; Klein AM; Dedeoglu A; Beal MF
    J Mol Neurosci; 2001 Aug; 17(1):89-96. PubMed ID: 11665866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis.
    Markert CD; Kim E; Gifondorwa DJ; Childers MK; Milligan CE
    J Med Food; 2010 Oct; 13(5):1081-5. PubMed ID: 20626250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motor neuron disease: a chemical perspective.
    Wood LK; Langford SJ
    J Med Chem; 2014 Aug; 57(15):6316-31. PubMed ID: 24694032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis.
    Kaspar BK; Frost LM; Christian L; Umapathi P; Gage FH
    Ann Neurol; 2005 May; 57(5):649-55. PubMed ID: 15852403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside.
    Gibson SB; Bromberg MB
    Semin Neurol; 2012 Jul; 32(3):173-8. PubMed ID: 23117941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerium oxide nanoparticles with antioxidant properties ameliorate strength and prolong life in mouse model of amyotrophic lateral sclerosis.
    DeCoteau W; Heckman KL; Estevez AY; Reed KJ; Costanzo W; Sandford D; Studlack P; Clauss J; Nichols E; Lipps J; Parker M; Hays-Erlichman B; Leiter JC; Erlichman JS
    Nanomedicine; 2016 Nov; 12(8):2311-2320. PubMed ID: 27389143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of peptide nucleic acid and selected conjugates against specific cellular pathologies of amyotrophic lateral sclerosis.
    Browne EC; Parakh S; Duncan LF; Langford SJ; Atkin JD; Abbott BM
    Bioorg Med Chem; 2016 Apr; 24(7):1520-7. PubMed ID: 26935939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metallothionein is a Potential Therapeutic Strategy for Amyotrophic Lateral Sclerosis.
    Ono SI
    Curr Pharm Des; 2017; 23(33):5001-5009. PubMed ID: 28641540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
    Di Matteo V; Esposito E
    Curr Drug Targets CNS Neurol Disord; 2003 Apr; 2(2):95-107. PubMed ID: 12769802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Catalytic antioxidants to treat amyotropic lateral sclerosis.
    Crow JP
    Expert Opin Investig Drugs; 2006 Nov; 15(11):1383-93. PubMed ID: 17040198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel decoy that interrupts G93A-superoxide dismutase gain of interaction with malate dehydrogenase improves survival in an amyotrophic lateral sclerosis cell model.
    Mali Y; Zisapel N
    J Med Chem; 2009 Sep; 52(17):5442-8. PubMed ID: 19670830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell-permeable, mitochondrial-targeted, peptide antioxidants.
    Szeto HH
    AAPS J; 2006 Apr; 8(2):E277-83. PubMed ID: 16796378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neuro-degenerative diseases: role of reactive oxygen species and of apoptosis].
    Follézou JY; Emerit J; Bricaire F
    Presse Med; 1999 Oct; 28(30):1661-6. PubMed ID: 10544701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of preclinical trial timing - a potential reason for the disconnect between mouse studies and human clinical trials in ALS.
    Kong Q; Carothers S; Chang Y; Glenn Lin CL
    CNS Neurosci Ther; 2012 Sep; 18(9):791-3. PubMed ID: 22712693
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.